Data from Takeda Pharmaceutical Co. Ltd. Provide New Insights into Amyotrophic Lateral Sclerosis (Neuroinflammation and glycosylation-related cerebrospinal fluid proteins for predicting functional decline in amyotrophic lateral sclerosis: a...).

A recent study by Takeda Pharmaceutical Co. Ltd. in Fujisawa, Japan, focused on amyotrophic lateral sclerosis (ALS) and the search for prognostic biomarkers to predict disease progression. The study analyzed cerebrospinal fluid (CSF) samples from ALS patients and disease controls, identifying proteins related to neuroinflammation and glycosylation that were significantly correlated with disease progression rates. The findings suggest that these proteins could serve as useful prognostic biomarkers for ALS, potentially improving clinical trial design and patient care. [Extracted from the article]